ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Insulin Production of UNDBIO Supported by Sen. Manchin and WV Officials

By: NewsUSA

(NewsUSA) - In a landmark Memorandum of Understanding (MOU) signed on May 17, 2022, by Mitch Carmichael, the Secretary of State for Economic Development of West Virginia, and Yong Soo Jun, Chairman of UNDBIO, Inc. the State of West Virginia agreed to provide fiscal, tax, and other incentives to promote UNDBIO’s production of insulin in West Virginia.  Secretary Carmichael also pledged to work with state, county, and local officials to promote UNDBIO’s insulin production.     

The purpose of the MOU is to meet the need for reasonably priced insulin in the United States and North America, as currently over 50 million persons are suffering from diabetes in the United States. In West Virginia alone 16 percent of the adult population suffers from diabetes.  The most commonly used forms of analogue insulin cost 10 times more in the United States than in any other developed country.     

UNDBIO estimates that its manufacture of insulin will create 1,200 new jobs in West Virginia and result in the transfer of its innovative technology platforms including human insulin, insulin analogues, and delivery innovation such as insulin sustained release injection.     

UNDBIO will commence its research and construction of its West Virginia manufacturing plant in the second half of 2022, complete its pilot facility in 2023, and manufacture clinical drugs for human clinical trials in 2024.     

“I am happy to establish our relationship with the State of West Virginia to manufacture affordable insulin and insulin analogues for the diabetic population around the globe,” said UNDBIO’s Chairman Jun. “We would welcome other partners and investors into our global insulin project,” he said.     

UNDBIO officials recently met with U.S. Senator Joe Manchin (D-W.Va.), who said, “UNDBIO has showcased their commitment to bringing long-term, good-paying jobs to West Virginia and as UNDBIO, WVU and state officials continue discussions, my staff and I are prepared to support these efforts to bring manufacturing opportunities to the Mountain State.”     

Support is echoed by U.S. Senator Shelley Moore Capito (R-W.Va.), who said “The news of this agreement between UNDBIO and the State of West Virginia is a positive step forward in UNDBIO’s quest to manufacture insulin right here in West Virginia. While there is still more work to do to finalize this new facility, I stand ready to help to make sure this becomes a reality. I congratulate UNDBIO on this advancement and look forward to supporting them in their investment that could lead to creating more than 1,000 jobs in West Virginia.”     

UNDBIO has signed a Memorandum of Understanding indicating its intention to manufacture insulin at the Research Park owned by West Virginia University (WVU) in Morgantown, West Virginia. The support of federal and state officials of West Virginia was echoed by Gordon Gee, President of West Virginia University, who said, “We look forward to building a strong relationship with UNDBIO that can further an important part of our land-grant mission to provide opportunities for better access to health care.”     

For further information, contact: Dr. Haiching Zhao/UNDBIO, haichingz@yahoo.com; Tel: 240-234-4717.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.22
+4.06 (1.77%)
AAPL  278.85
+1.30 (0.47%)
AMD  217.53
+3.29 (1.54%)
BAC  53.65
+0.66 (1.25%)
GOOG  320.12
-0.16 (-0.05%)
META  647.95
+14.34 (2.26%)
MSFT  492.01
+6.51 (1.34%)
NVDA  177.00
-3.26 (-1.81%)
ORCL  201.95
-3.01 (-1.47%)
TSLA  430.17
+3.59 (0.84%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.